Current Stock Performance and Analyst Ratings Allogene Therapeutics (NASDAQ: ALLO) is currently trading at approximately $2.80 per share. Over the past year, the stock has experienced significant volatility, reflecting both the high potential and risks associated with the biotech sector, particularly in clinical-stage companies like Allogene. MarketBeat, Stock Analysis Analyst consensus currently rates ALLO as a […]
Puronix: Bridging Science and Innovation
Unveiling the Core of Biotechnology and Its Real-World Applications